We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Cancer Treatments Made More Powerful with Fewer Side Effects

By LabMedica International staff writers
Posted on 16 Dec 2010
Scientists are having initial success in new combined therapies to deliver cancer treatments that target only the tumor without damaging normal tissue. More...


One new therapy uses nanoparticles, such as carbon nanotubes (CNTs), for drug delivery. Another new therapy that has been used is nonthermal irreversible electroporation (N-TIRE). The principle behind this therapy has been known since 1898 as a method to treat bacteria-infested water, but it is now being used in the treatment of cancer. N-TIRE is the application of electrical fields to a targeted tissue area with the purpose of permanently opening pores in the membranes of a cell, causing cell death. The destruction of the cells in this instance is not due to thermal injury--significant since it allows the elimination of tumor cells while respecting normal tissue.

Dr. Rafael Davalos, a bioengineer at Virginia Polytechnic Institute and State University (Virginia Tech; Blacksburg, USA) and coinventor of N-TIRE, is doing a study combining N-TIRE and CNTs. He is using N-TIRE to treat the tumor and CNTs to target selectively cancer cells inside a tumor and cancer cells that have already moved throughout the body. "The procedure is essentially done with two minimally invasive electrodes placed into the targeted region," Dr. Davalos said, "delivering approximately 80 pulses to the site in about one minute. The pulses are high voltage, but low energy, so no significant heating occurs as a result of the procedure."

Lack of heat is important for structures such as nerves and major blood vessels, according to Dr. Davalos, as this preserves the tissues and allows treatment of previously inoperable tumors. Although the procedure has submillimeter resolution, he adds, the injected nanoparticles improve targeting even further.

Typically, most studies report minimal side effects in the treatment with N-TIRE, but there are some apprehension about therapies with CNTs, since researchers have seen some effects such as excessive inflammatory response and formation of free radicals in some trials. "N-TIRE can be safely used right now," Dr. Davalos said. "However, if we combine N-TIRE with another therapy, we need to be careful with the choice of nanoparticle to ensure no toxicity to the body."

N-TIRE was utilized for the first time in humans in 2008 for prostate cancer treatment, with promising results. New trials are being conducted for lung, kidney, hepatic, and other cancers. Carbon nanotubes, hypothetically, are very promising as a cancer therapy, but more research needs to be done to address toxicity. "The combined therapy of CNTs plus N-TIRE can be used to treat any type of cancer including brain, prostate, kidney, liver, and pancreatic, but is limited in that it is a focal technique," Dr. Davalos added. "In other words, only one 2 cm to 3 cm site can be treated at a given time. One of the objectives of the research is to increase the zone that can be treated using a single procedure."

Similar to any focal treatment, this combinatorial therapy will typically be used in conjunction with a traditional treatment, until its efficiency can be broadly demonstrated. "This technique would most likely be used in conjunction with other therapies that are the standard of care," Dr. Davolos said. "However, it can be used independently, and also can be used as a salvage therapy when other techniques are no longer effective."

Related Links:
Virginia Polytechnic Institute and State University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.